|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02252 MEDBOT-B
Nominal 
25.740 +0.560 (+2.224%) | 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Turnover | 551,069 | 114.216% | 257,249 | 104,592 | 21,603 | 2,150 |
| Cost of Sales | (284,447) | 66.315% | (171,029) | (89,898) | (15,041) | (1,231) |
| Gross Profit | 266,622 | 209.235% | 86,220 | 14,694 | 6,562 | 919 |
| 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | (31,316) | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | 1,995 | -- | (116,467) | -- | -- | -- | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | (1,040) | -94.863% | (20,244) | (29,803) | (39,655) | (27,377) | |
| Profit / (Loss) before Taxation | (254,115) | -60.730% | (647,101) | (1,023,530) | (1,146,284) | (584,507) | |
| Taxation | 0 | -- | 0 | 0 | 0 | 0 | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 4,455 | -5.112% | 4,695 | 11,356 | 6,478 | 1,586 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | (249,660) | -61.137% | (642,406) | (1,012,174) | (1,139,806) | (582,921) | |
| 2025/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 12,975 | -33.263% | 19,442 | 9,716 | (15,287) | (16,638) |
| Depreciation & Amortisation | 108,974 | -7.527% | 117,844 | 111,759 | 100,706 | 35,373 |
| Directors' Emoluments | -- | -- | 12,596 | 45,868 | 46,486 | 36,843 |
| 2025/12 - Final | %Chg (Compare to Final) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2025/12 - Final | %Chg (Compare to Final) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| EPS (cts) | -24.000 | -63.636% | -66.000 | -106.000 | -119.000 | -63.000 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | 0.000 |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | -- | -- | (0.308) | (0.592) | (0.937) | (0.588) |
| NBV per share ($) | 0.398 | -- | 0.276 | 0.542 | 1.479 | 2.497 |
| Remarks: | Real time quote last updated: 27/03/2026 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB -249,660 |
| %Change | -61.137% |
| EPS / (LPS) | RMB -0.240 |
| NBV Per Share (¥) | RMB 0.398 |